Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.75) price target on GlaxoSmithKline plc (LON:GSK) in a report issued on Wednesday. The firm currently has a buy rating on the stock.

Other research analysts have also issued reports about the company. Jefferies Group LLC cut their price objective on GlaxoSmithKline plc from GBX 1,850 ($24.10) to GBX 1,800 ($23.45) and set a buy rating on the stock in a research report on Thursday, April 20th. Liberum Capital reissued a buy rating and issued a GBX 1,900 ($24.75) price objective on shares of GlaxoSmithKline plc in a research report on Thursday, March 30th. HSBC Holdings plc reissued a buy rating and issued a GBX 1,970 ($25.66) price objective on shares of GlaxoSmithKline plc in a research report on Thursday, April 27th. Beaufort Securities reissued a buy rating and issued a GBX 1,750 ($22.80) price objective on shares of GlaxoSmithKline plc in a research report on Thursday, April 27th. Finally, Berenberg Bank raised GlaxoSmithKline plc from a hold rating to a buy rating and raised their price objective for the company from GBX 1,850 ($24.10) to GBX 1,885 ($24.56) in a research report on Friday, May 26th. Four analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of GBX 1,734.73 ($22.60).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1518.50 on Wednesday. The firm’s 50-day moving average price is GBX 1,638.77 and its 200 day moving average price is GBX 1,627.17. GlaxoSmithKline plc has a one year low of GBX 1,446.50 and a one year high of GBX 1,745.56. The stock’s market cap is GBX 74.22 billion.

TRADEMARK VIOLATION WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.watchlistnews.com/goldman-sachs-group-inc-the-reiterates-gbx-1900-price-target-for-glaxosmithkline-plc-longsk/1461900.html.

The company also recently disclosed a dividend, which will be paid on Thursday, October 12th. Investors of record on Thursday, August 10th will be issued a GBX 19 ($0.25) dividend. This represents a yield of 1.23%. The ex-dividend date is Thursday, August 10th.

In other news, insider Patrick Vallance acquired 861 shares of the stock in a transaction that occurred on Friday, July 14th. The stock was purchased at an average cost of GBX 1,618 ($21.08) per share, with a total value of £13,930.98 ($18,148.75). Also, insider Manvinder Singh Banga acquired 2,267 shares of the stock in a transaction that occurred on Wednesday, July 26th. The stock was purchased at an average cost of GBX 1,599 ($20.83) per share, with a total value of £36,249.33 ($47,224.24). Over the last three months, insiders purchased 3,150 shares of company stock valued at $5,054,075.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.